Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43845   clinical trials with a EudraCT protocol, of which   7282   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A phase III, open-label, multicentre study to evaluate the immunogenicity, safety and reactogenicity of a re-vaccination dose of the GlaxoSmithKline Biologicals' quadrivalent seasonal influenza candidate vaccine GSK2321138A, administered to children who previously participated in study 115345 (FLU D-QIV-004 PRI).

    Summary
    EudraCT number
    		 2012-001230-34
    Trial protocol
    		 ES   CZ   GB   PL  
    Global end of trial date
    05 Jun 2013

    Results information
    Results version number
    		 v4(current)
    This version publication date
    16 Sep 2018
    First version publication date
    02 May 2015
    Other versions
    		 v1 (removed from public view) , v2 , v3
    Version creation reason
    • Correction of full data set
    Results have been amended to account for consistency with other registries.

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    116023
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT01702454
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    GlaxoSmithKline Biologicals
    Sponsor organisation address
    Rue de l'Institut 89, Rixensart, Belgium,
    Public contact
    Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
    Scientific contact
    Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    Yes
    EMA paediatric investigation plan number(s)
    		 EMEA-000817-PIP02-11
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    11 Dec 2013
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    05 Jun 2013
    Global end of trial reached?
    Yes
    Global end of trial date
    05 Jun 2013
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To assess the immune response in terms of Haemagglutination Inhibition (HI) antibody titre at Day 7 after one dose of FLU D-QIV vaccine (2012-2013 formulation) in vaccine-primed and vaccine-unprimed subjects, for all strains included in the vaccine.
    Protection of trial subjects
    All subjects were supervised closely for at least 30 minutes following vaccination with appropriate medical treatment readily available. Vaccines were administered by qualified and trained personnel. Vaccines/products were administered only to eligible subjects that had no contraindications to any components of the vaccines. Subjects were followed-up from the time the subject consents to participate in the study until she/he is discharged.
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    06 Oct 2012
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Poland: 103
    Country: Number of subjects enrolled
    Spain: 149
    Country: Number of subjects enrolled
    United Kingdom: 83
    Country: Number of subjects enrolled
    Czech Republic: 135
    Worldwide total number of subjects
    470
    EEA total number of subjects
    470
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    470
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 An additional pre-specified immunogenicity analysis was conducted on According-to-Protocol cohort for immunogenicity (ATP-I) excluding subjects who had an RT-PCR confirmed influenza infection in study 115345 and was dependent on the unblinding of the parent study, 115345. Micro-neutralising/Anti-neuraminidase analysis was done by age strata too.

    Pre-assignment
    Screening details
    		 During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Randomised - controlled
    Blinding used
    		 Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 Fluarix Quadrivalent Primed Group
    Arm description
    		 Subjects in this group were previously primed with 2 doses of Fluarix Quadrivalent vaccine in the primary study 115345 (NCT01439360) and received 1 dose of Fluarix Quadrivalent vaccine at Day 0 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.
    Arm type
    		 Experimental

    Investigational medicinal product name
    Fluarix Quadrivalent
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Vaccine-primed subjects received a single 0.5 mL dose administered intramuscularly at Visit 1 (Day 0). Vaccines were administered in the deltoid region.

    Arm title
    		 Fluarix Quadrivalent Unprimed Group
    Arm description
    		 Subjects in this group were unprimed in the primary study 115345 (NCT01439360) and received 2 doses of Fluarix Quadrivalent vaccine at Days 0 and 28 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.
    Arm type
    		 Experimental

    Investigational medicinal product name
    Fluarix Quadrivalent
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Vaccine-unprimed subjects received one 0.5 mL dose administered intramuscularly at Visit 1 (Day 0) and one 0.5 mL dose administered intramuscularly at Visit 3 (Day 28). Vaccines were administered in the deltoid region.

    Number of subjects in period 1
    		Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Started
    241
    229
    Completed
    238
    221
    Not completed
    3
    8
         Consent withdrawal
    -
    1
         Migrated/moved from study area
    -
    1
         Lost to follow-up
    3
    6

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Fluarix Quadrivalent Primed Group
    Reporting group description
    		 Subjects in this group were previously primed with 2 doses of Fluarix Quadrivalent vaccine in the primary study 115345 (NCT01439360) and received 1 dose of Fluarix Quadrivalent vaccine at Day 0 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.

    Reporting group title
    Fluarix Quadrivalent Unprimed Group
    Reporting group description
    		 Subjects in this group were unprimed in the primary study 115345 (NCT01439360) and received 2 doses of Fluarix Quadrivalent vaccine at Days 0 and 28 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.

    Reporting group values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group Total
    Number of subjects
    		 241 229
    Age categorical
    Units: Subjects
    Age continuous
    Age continuous description
    Units: years
        arithmetic mean (standard deviation)
    		 33.2 ( 7.54 ) 32.5 ( 7.39 ) -
    Gender categorical
    Gender categorical description
    Units: Subjects
        Female
    		 114 96 210
        Male
    		 127 133 260

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    Fluarix Quadrivalent Primed Group
    Reporting group description
    		 Subjects in this group were previously primed with 2 doses of Fluarix Quadrivalent vaccine in the primary study 115345 (NCT01439360) and received 1 dose of Fluarix Quadrivalent vaccine at Day 0 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.

    Reporting group title
    Fluarix Quadrivalent Unprimed Group
    Reporting group description
    		 Subjects in this group were unprimed in the primary study 115345 (NCT01439360) and received 2 doses of Fluarix Quadrivalent vaccine at Days 0 and 28 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.

    Primary: Serum Hemagglutination Inhibition (HI) antibody titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine

    		 Close Top of page
    End point title
    		 Serum Hemagglutination Inhibition (HI) antibody titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine
    End point description
    Antibody titers were expressed as Geometric Mean Titers (GMTs). The vaccine strains included A/Christchurch/16/2010 ( H1N1), A/Victoria/361/2011 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens.
    End point type
    Primary
    End point timeframe
    At Day 0 and Day 7
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    224
    209
    Units: Titer
    geometric mean (confidence interval 95%)
        H1N1, Day 0 [N=221,202]
    43.1 (33.8 to 54.9)
    14.5 (11.5 to 18.2)
        H1N1, Day 7 [N=224,209]
    445.6 (376.9 to 526.7)
    45.8 (32 to 65.5)
        H3N2, Day 0 [N=221,202]
    12.3 (10.7 to 14.1)
    16.4 (13.2 to 20.4)
        H3N2, Day 7 [N=224,209]
    135.3 (113.6 to 161.2)
    47.5 (32.6 to 69.3)
        Victoria, Day 0 [N=221,202]
    28.5 (23.8 to 34.1)
    10 (8.4 to 11.9)
        Victoria, Day 7 [N=224,209]
    193.9 (168.7 to 222.8)
    47.1 (35.2 to 63)
        Yamagata, Day 0 [N=221,202]
    11.9 (10.6 to 13.3)
    6.5 (5.9 to 7.2)
        Yamagata, Day 7 [N=224,209]
    182.6 (159 to 209.6)
    26.1 (20.9 to 32.7)
    Statistical analysis title
    		 Adjusted GMT ratio for A/Christchurch antibodies
    Statistical analysis description
    The adjusted GMT of HI antibodies for A/Christchurch strain at post-vaccination dose 1, the GMT ratio of Fluarix Quadrivalent Primed Group/Fluarix Quadrivalent Unprimed Group and the 2-sided 95% CI on each GMT ratio were computed after fitting an ANCOVA model on the logarithm10 transformation of the titers, including the vaccine group as fixed effect and the pre-vaccination log-10 titer and age as regressors.
    Comparison groups
    Fluarix Quadrivalent Primed Group v Fluarix Quadrivalent Unprimed Group
    Number of subjects included in analysis
    433
    Analysis specification
    Pre-specified
    Analysis type
    		 non-inferiority [1]
    Method
    Parameter type
    		 Adjusted GMT Ratio
    Point estimate
    8.97
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 6.21
         upper limit
    		 12.96
    Notes
    [1] - Criterion: The lower limit (LL) of the two-sided 95% Confidence Interval (CI) for the GMT ratio is above 1. The GMTs were used to calculate the Adjusted GMTs, which in turn were used to calculate the Adjusted GMT ratio with 95% confidence interval.
    Statistical analysis title
    		 Adjusted GMT ratio for A/Victoria antibodies
    Statistical analysis description
    The adjusted GMT of HI antibodies for A/Victoria strain at post-vaccination dose 1, the GMT ratio of Fluarix Quadrivalent Primed Group/Fluarix Quadrivalent Unprimed Group and the 2-sided 95% CI on each GMT ratio were computed after fitting an ANCOVA model on the logarithm10 transformation of the titers, including the vaccine group as fixed effect and the pre-vaccination log-10 titer and age as regressors.
    Comparison groups
    Fluarix Quadrivalent Primed Group v Fluarix Quadrivalent Unprimed Group
    Number of subjects included in analysis
    433
    Analysis specification
    Pre-specified
    Analysis type
    		 non-inferiority [2]
    Method
    Parameter type
    		 Adjusted GMT Ratio
    Point estimate
    2.7
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 1.81
         upper limit
    		 4.02
    Notes
    [2] - Criterion: The lower limit (LL) of the two-sided 95% Confidence Interval (CI) for the GMT ratio is above 1. The GMTs were used to calculate the Adjusted GMTs, which in turn were used to calculate the Adjusted GMT ratio with 95% confidence interval.
    Statistical analysis title
    		 Adjusted GMT ratio for B/Brisbane antibodies
    Statistical analysis description
    The adjusted GMT of HI antibodies for B/Brisbane strain at post-vaccination dose 1, the GMT ratio of Fluarix Quadrivalent Primed Group/Fluarix Quadrivalent Unprimed Group and the 2-sided 95% CI on each GMT ratio were computed after fitting an ANCOVA model on the logarithm10 transformation of the titers, including the vaccine group as fixed effect and the pre-vaccination log-10 titer and age as regressors.
    Comparison groups
    Fluarix Quadrivalent Primed Group v Fluarix Quadrivalent Unprimed Group
    Number of subjects included in analysis
    433
    Analysis specification
    Pre-specified
    Analysis type
    		 non-inferiority [3]
    Method
    Parameter type
    		 Adjusted GMT Ratio
    Point estimate
    3.94
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 2.89
         upper limit
    		 5.37
    Notes
    [3] - Criterion: The lower limit (LL) of the two-sided 95% Confidence Interval (CI) for the GMT ratio is above 1. The GMTs were used to calculate the Adjusted GMTs, which in turn were used to calculate the Adjusted GMT ratio with 95% confidence interval.
    Statistical analysis title
    		 Adjusted GMT ratio for B/Hub-Wuj antibodies
    Statistical analysis description
    The adjusted GMT of HI antibodies for B/Hub-Wuj strain at post-vaccination dose 1, the GMT ratio of Fluarix Quadrivalent Primed Group/Fluarix Quadrivalent Unprimed Group and the 2-sided 95% CI on each GMT ratio were computed after fitting an ANCOVA model on the logarithm10 transformation of the titers, including the vaccine group as fixed effect and the pre-vaccination log-10 titer and age as regressors.
    Comparison groups
    Fluarix Quadrivalent Primed Group v Fluarix Quadrivalent Unprimed Group
    Number of subjects included in analysis
    433
    Analysis specification
    Pre-specified
    Analysis type
    		 non-inferiority [4]
    Method
    Parameter type
    		 Adjusted GMT Ratio
    Point estimate
    6.71
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 5.21
         upper limit
    		 8.63
    Notes
    [4] - Criterion: The lower limit (LL) of the two-sided 95% Confidence Interval (CI) for the GMT ratio is above 1. The GMTs were used to calculate the Adjusted GMTs, which in turn were used to calculate the Adjusted GMT ratio with 95% confidence interval.

    Primary: Number of seropositive subjects against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine

    		 Close Top of page
    End point title
    		 Number of seropositive subjects against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine [5]
    End point description
    Seropositivity was defined as number of subjects with antibody titers greater than or equal to (≥) 1:10. The vaccine strains included A/Christchurch/16/2010 ( H1N1), A/Victoria/361/2011 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens.
    End point type
    Primary
    End point timeframe
    At Day 0 and Day 7
    Notes
    [5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    224
    209
    Units: Subjects
        H1N1, Day 0 [N=221,202]
    189
    64
        H1N1, Day 7 [N=224,209]
    220
    137
        H3N2, Day 0 [N=221,202]
    131
    79
        H3N2, Day 7 [N=224,209]
    218
    99
        Victoria, Day 0 [N=221,202]
    187
    58
        Victoria, Day 7 [N=224,209]
    224
    174
        Yamagata, Day 0 [N=221,202]
    134
    36
        Yamagata, Day 7 [N=224,209]
    222
    144
    No statistical analyses for this end point

    Primary: Number of subjects seroconverted for HI antibodies against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine.

    		 Close Top of page
    End point title
    		 Number of subjects seroconverted for HI antibodies against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine.
    End point description
    A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/Christchurch/16/2010 ( H1N1), A/Victoria/361/2011 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens.
    End point type
    Primary
    End point timeframe
    At Day 7 post dose 1
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    221
    202
    Units: Subjects
        H1N1
    170
    65
        H3N2
    180
    73
        Victoria
    169
    78
        Yamagata
    208
    77
    Statistical analysis title
    		 Difference in SCR for A/Christchurch antibodies
    Statistical analysis description
    To assess the immune response in terms of SCR difference at Day 7 after one dose of Fluarix Quadrivalent vaccine (2012-2013 formulation) in vaccine-primed and vaccine-unprimed subjects, for all the strains.
    Comparison groups
    Fluarix Quadrivalent Primed Group v Fluarix Quadrivalent Unprimed Group
    Number of subjects included in analysis
    423
    Analysis specification
    Pre-specified
    Analysis type
    		 non-inferiority [6]
    Method
    Parameter type
    		 Difference in percentages
    Point estimate
    44.74
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 35.87
         upper limit
    		 52.84
    Notes
    [6] - SCR difference was calculated using standardized asymptotic 95% CI for the group difference in proportion.
    Statistical analysis title
    		 Difference in SCR for A/Victoria antibodies
    Statistical analysis description
    To assess the immune response in terms of SCR difference at Day 7 after one dose of Fluarix Quadrivalent vaccine (2012-2013 formulation) in vaccine-primed and vaccine-unprimed subjects, for all the strains.
    Comparison groups
    Fluarix Quadrivalent Primed Group v Fluarix Quadrivalent Unprimed Group
    Number of subjects included in analysis
    423
    Analysis specification
    Pre-specified
    Analysis type
    		 non-inferiority [7]
    Method
    Parameter type
    		 Difference in percentages
    Point estimate
    45.31
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 36.58
         upper limit
    		 53.3
    Notes
    [7] - SCR difference was calculated using standardized asymptotic 95% CI for the group difference in proportion.
    Statistical analysis title
    		 Difference in SCR for B/Brisbane antibodies
    Statistical analysis description
    To assess the immune response in terms of SCR difference at Day 7 after one dose of Fluarix Quadrivalent vaccine (2012-2013 formulation) in vaccine-primed and vaccine-unprimed subjects, for all the strains.
    Comparison groups
    Fluarix Quadrivalent Primed Group v Fluarix Quadrivalent Unprimed Group
    Number of subjects included in analysis
    423
    Analysis specification
    Pre-specified
    Analysis type
    		 non-inferiority [8]
    Method
    Parameter type
    		 Difference in percentages
    Point estimate
    37.86
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 28.83
         upper limit
    		 46.26
    Notes
    [8] - SCR difference was calculated using standardized asymptotic 95% CI for the group difference in proportion.
    Statistical analysis title
    		 Difference in SCR for B/Hu-Wuj antibodies
    Statistical analysis description
    To assess the immune response in terms of SCR difference at Day 7 after one dose of Fluarix Quadrivalent vaccine (2012-2013 formulation) in vaccine-primed and vaccine-unprimed subjects, for all the strains. B/Hu-Wuj = B/Hubei-Wujiagang/158/2009 (Yamagata)
    Comparison groups
    Fluarix Quadrivalent Primed Group v Fluarix Quadrivalent Unprimed Group
    Number of subjects included in analysis
    423
    Analysis specification
    Pre-specified
    Analysis type
    		 non-inferiority [9]
    Method
    Parameter type
    		 Difference in percentages
    Point estimate
    56
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 48.32
         upper limit
    		 63.04
    Notes
    [9] - SCR difference was calculated using standardized asymptotic 95% CI for the group difference in proportion.

    Primary: Mean geometric increase (MGI) for HI antibody titer against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine.

    		 Close Top of page
    End point title
    		 Mean geometric increase (MGI) for HI antibody titer against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine. [10]
    End point description
    MGI was defined as the fold increase in serum HI GMT post-vaccination compared to Day 0. The vaccine strains included A/Christchurch/16/2010 (H1N1), A/Victoria/361/2011 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens.
    End point type
    Primary
    End point timeframe
    At Day 7 post dose 1
    Notes
    [10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    221
    202
    Units: Fold increase
    geometric mean (confidence interval 95%)
        H1N1
    10.3 (8.5 to 12.4)
    3.2 (2.6 to 3.9)
        H3N2
    10.9 (9.4 to 12.6)
    2.9 (2.4 to 3.6)
        Victoria
    6.7 (5.9 to 7.6)
    4.6 (3.8 to 5.5)
        Yamagata
    15.2 (13.3 to 17.3)
    4 (3.3 to 4.9)
    No statistical analyses for this end point

    Primary: Number of subjects seroprotected for anti-HA antibodies against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine.

    		 Close Top of page
    End point title
    		 Number of subjects seroprotected for anti-HA antibodies against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine.
    End point description
    Seroprotection rate (SPR) was defined as the number of vaccinees with serum haemagglutination inhibition (HI) titer ≥ 1:40 that usually is accepted as indicating protection in adults. The vaccine strains included A/Christchurch/16/2010 ( H1N1), A/Victoria/361/2011 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens.
    End point type
    Primary
    End point timeframe
    At Day 0 and Day 7
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    224
    209
    Units: Subjects
        H1N1, Day 0 [N=221,202]
    89
    61
        H1N1, Day 7 [N=224,209]
    217
    72
        H3N2, Day 0 [N=221,202]
    37
    74
        H3N2, Day 7 [N=224,209]
    193
    81
        Victoria, Day 0 [N=221,202]
    72
    39
        Victoria, Day 7 [N=224,209]
    217
    84
        Yamagata, Day 0 [N=221,202]
    27
    12
        Yamagata, Day 7 [N=224,209]
    216
    83
    Statistical analysis title
    		 Difference in SPR for A/Christ antibodies
    Statistical analysis description
    To assess the immune response in terms of SPR difference at Day 7 after one dose of Fluarix Quadrivalent vaccine (2012-2013 formulation) in vaccine-primed and vaccine-unprimed subjects, for all the strains.
    Comparison groups
    Fluarix Quadrivalent Primed Group v Fluarix Quadrivalent Unprimed Group
    Number of subjects included in analysis
    433
    Analysis specification
    Pre-specified
    Analysis type
    		 non-inferiority [11]
    Method
    Parameter type
    		 Difference in SPR
    Point estimate
    62.43
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 55.27
         upper limit
    		 68.89
    Notes
    [11] - SPR difference was calculated using standardized asymptotic 95% CI for the group difference in proportion.
    Statistical analysis title
    		 Difference in SPR for A/Victoria antibodies
    Statistical analysis description
    To assess the immune response in terms of SPR difference at Day 7 after one dose of Fluarix Quadrivalent vaccine (2012-2013 formulation) in vaccine-primed and vaccine-unprimed subjects, for all the strains.
    Comparison groups
    Fluarix Quadrivalent Primed Group v Fluarix Quadrivalent Unprimed Group
    Number of subjects included in analysis
    433
    Analysis specification
    Pre-specified
    Analysis type
    		 non-inferiority [12]
    Method
    Parameter type
    		 Difference in SPR
    Point estimate
    47.4
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 39.08
         upper limit
    		 55.06
    Notes
    [12] - SPR difference was calculated using standardized asymptotic 95% CI for the group difference in proportion.
    Statistical analysis title
    		 Difference in SPR for B/Brisbane antibodies
    Statistical analysis description
    To assess the immune response in terms of SPR difference at Day 7 after one dose of Fluarix Quadrivalent vaccine (2012-2013 formulation) in vaccine-primed and vaccine-unprimed subjects, for all the strains.
    Comparison groups
    Fluarix Quadrivalent Primed Group v Fluarix Quadrivalent Unprimed Group
    Number of subjects included in analysis
    433
    Analysis specification
    Pre-specified
    Analysis type
    		 non-inferiority [13]
    Method
    Parameter type
    		 Difference in SPR
    Point estimate
    56.68
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 49.44
         upper limit
    		 63.43
    Notes
    [13] - SPR difference was calculated using standardized asymptotic 95% CI for the group difference in proportion.
    Statistical analysis title
    		 Difference in SPR for B/Hub-Wuj antibodies
    Statistical analysis description
    To assess the immune response in terms of SCR difference at Day 7 after one dose of Fluarix Quadrivalent vaccine (2012-2013 formulation) in vaccine-primed and vaccine-unprimed subjects, for all the strains. The B/Hub-Wuj = B/Hubei-Wujiagang/158/2009 (Yamagata)
    Comparison groups
    Fluarix Quadrivalent Primed Group v Fluarix Quadrivalent Unprimed Group
    Number of subjects included in analysis
    433
    Analysis specification
    Pre-specified
    Analysis type
    		 non-inferiority [14]
    Method
    Parameter type
    		 Difference in SPR
    Point estimate
    56.72
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 49.41
         upper limit
    		 63.49
    Notes
    [14] - SPR difference was calculated using standardized asymptotic 95% CI for the group difference in proportion.

    Primary: Serum Hemagglutination Inhibition (HI) antibody titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine.

    		 Close Top of page
    End point title
    		 Serum Hemagglutination Inhibition (HI) antibody titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine. [15]
    End point description
    Antibody titers were expressed as Geometric Mean Titers (GMTs). The vaccine strains included A/Christchurch/16/2010 ( H1N1), A/Victoria/361/2011 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens.
    End point type
    Primary
    End point timeframe
    At Day 0 and Day 7
    Notes
    [15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    213
    179
    Units: Titers
    geometric mean (confidence interval 95%)
        H1N1, Day 0 [N=210,173]
    44 (34.2 to 56.7)
    14.3 (11.2 to 18.3)
        H1N1, Day 7 [N=213,179]
    442.3 (372 to 525.9)
    42.7 (29 to 63)
        H3N2, Day 0 [N=210,173]
    11 (9.8 to 12.5)
    11.9 (9.6 to 14.7)
        H3N2, Day 7 [N=213,179]
    125.9 (105.4 to 150.4)
    28.7 (19.7 to 41.9)
        Victoria, Day 0 [N=210,173]
    27.8 (23.2 to 33.2)
    10.3 (8.5 to 12.5)
        Victoria, Day 7 [N=213,179]
    193.3 (167.6 to 222.8)
    46.1 (33.5 to 63.4)
        Yamagata, Day 0 [N=210,173]
    11.9 (10.6 to 13.4)
    6.5 (5.8 to 7.2)
        Yamagata, Day 7 [N=213,179]
    184.1 (159.8 to 212.1)
    25.2 (19.8 to 32)
    No statistical analyses for this end point

    Primary: Number of subjects seropositive for HI antibody titers against each of the four vaccine strains after dose 1 of Fluarix Quadrivalent vaccine

    		 Close Top of page
    End point title
    		 Number of subjects seropositive for HI antibody titers against each of the four vaccine strains after dose 1 of Fluarix Quadrivalent vaccine [16]
    End point description
    Seropositivity was defined as number of subjects with antibody titers greater than or equal to (≥) 1:10. The vaccine strains included A/Christchurch/16/2010 ( H1N1), A/Victoria/361/2011 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens.
    End point type
    Primary
    End point timeframe
    At Day 0 and Day 7
    Notes
    [16] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    213
    179
    Units: Subjects
        H1N1, Day 0 [N=210,173]
    178
    54
        H1N1, Day 7 [N=213,179]
    209
    113
        H3N2, Day 0 [N=210,173]
    120
    52
        H3N2, Day 7 [N=213,179]
    207
    72
        Victoria, Day 0[ N=210,173]
    177
    50
        Victoria, Day 7[ N=213,179]
    213
    145
        Yamagata, Day 0[ N=210,173]
    127
    31
        Yamagata, Day 7 [N=213,179]
    211
    120
    No statistical analyses for this end point

    Primary: Number of subjects seroconverted for HI antibodies against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine.

    		 Close Top of page
    End point title
    		 Number of subjects seroconverted for HI antibodies against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine. [17]
    End point description
    A seroconverted subject was defined as a subject who had either a pre-vaccination titer <1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a four-fold increase in post-vaccination titer. The vaccine strains included A/Christchurch/16/2010 ( H1N1), A/Victoria/361/2011 (H3N2), B/Brisbane/60/2008 (Victoria)and B/Hubei-Wujiagang/158/2009 (Yamagata )antigens.
    End point type
    Primary
    End point timeframe
    At Day 7 post dose 1
    Notes
    [17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    210
    173
    Units: Subjects
        H1N1, Day 7 [N=210,173]
    160
    54
        H3N2, Day 7 [N=210,173]
    173
    49
        Victoria, Day 7 [N=210,173]
    162
    66
        Yamagata, Day 7 [N=210,173]
    197
    65
    No statistical analyses for this end point

    Primary: Mean geometric increase (MGI) for HI antibody titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine.

    		 Close Top of page
    End point title
    		 Mean geometric increase (MGI) for HI antibody titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine. [18]
    End point description
    Mean geometric increase was defined as the geometric mean of the within subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer. The vaccine strains included A/Christchurch/16/2010 (H1N1), A/Victoria/361/2011(H3N2), B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens.
    End point type
    Primary
    End point timeframe
    At Day 7 post dose 1
    Notes
    [18] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    210
    173
    Units: Fold Increase
    geometric mean (confidence interval 95%)
        H1N1, Day 7 [N=210,173]
    10 (8.1 to 12.2)
    3.1 (2.5 to 3.9)
        H3N2, Day 7 [N=210,173]
    11.2 (9.7 to 13.1)
    2.4 (2 to 3)
        Victoria, Day 7 [N=210,173]
    6.9 (6 to 7.8)
    4.5 (3.7 to 5.4)
        Yamagata, Day 7 [N=210,173]
    15.2 (13.3 to 17.4)
    4 (3.2 to 4.9)
    No statistical analyses for this end point

    Primary: Number of subjects seroprotected for HI antibodies against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine.

    		 Close Top of page
    End point title
    		 Number of subjects seroprotected for HI antibodies against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine. [19]
    End point description
    Seroprotection rate was defined as the number of vaccinees with a serum HI titer greater than or equal to(≥) 1:40 that usually is accepted as indicating protection in adults. The vaccine strains included A/Christchurch/16/2010 (H1N1), A/Victoria/361/2011(H3N2), B/Brisbane/60/2008 (Victoria)and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens.
    End point type
    Primary
    End point timeframe
    At Day 0 and Day 7
    Notes
    [19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    213
    179
    Units: Subjects
        H1N1,Day 0 [N=210,173]
    87
    51
        H1N1, Day 7 [N=213,179]
    206
    59
        H3N2, Day 0 [N=210,173]
    29
    48
        H3N2, Day 7 [N=213,179]
    182
    54
        Victoria, Day 0 [N=210,173]
    68
    35
        Victoria, Day 7 [N=213,179]
    206
    70
        Yamagata, Day 0 [N=210,173]
    27
    10
        Yamagata, Day 7 [N=213,179]
    205
    70
    No statistical analyses for this end point

    Secondary: Number of subjects with HI antibody titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine.

    		 Close Top of page
    End point title
    		 Number of subjects with HI antibody titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine.
    End point description
    The cut-off values assessed were less than (<) 1:10, 1:10 to < 1:40 and ≥ 1:40. The vaccine strains included A/Christchurch/16/2010 ( H1N1), A/Victoria/361/2011 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens.
    End point type
    Secondary
    End point timeframe
    At Day 0 and Day 7
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    224
    209
    Units: Subjects
        H1N1 (<1:10), Day 0 [N=221,202]
    32
    138
        H1N1 (<1:10), Day 7 [N=224,209]
    4
    72
        H3N2 (<1:10), Day 0 [N=221,202]
    90
    123
        H3N2 (<1:10), Day 7 [N=224,209]
    6
    110
        Victoria (<1:10), Day 0 [N=221,202]
    34
    144
        Victoria (<1:10), Day 7 [N=224,209]
    0
    35
        Yamagata (<1:10), Day 0 [N=221,202]
    87
    166
        Yamagata (<1:10), Day 7 [N=224,209]
    2
    65
        H1N1 (1:10 to <1:40), Day 0 [N=221,202]
    100
    3
        H1N1 (1:10 to <1:40), Day 7 [N=224,209]
    3
    65
        H3N2 (1:10 to <1:40), Day 0 [N=221,202]
    94
    5
        H3N2 (1:10 to <1:40), Day 7 [N=224,209]
    25
    18
        Victoria (1:10 to <1:40), Day 0 [N=221,202]
    115
    19
        Victoria (1:10 to <1:40), Day 7 [N=224,209]
    7
    90
        Yamagata (1:10 to <1:40), Day 0 [N=221,202]
    107
    24
        Yamagata (1:10 to <1:40), Day 7 [N=224,209]
    6
    61
        H1N1 (≥1: 40), Day 0 [N=221,202]
    89
    61
        H1N1 (≥1: 40), Day 7 [N=224,209]
    217
    72
        H3N2 (≥1: 40), Day 0 [N=221,202]
    37
    74
        H3N2 (≥1: 40), Day 7 [N=224,209]
    193
    81
        Victoria (≥1: 40), Day 0 [N=221,202]
    72
    39
        Victoria (≥1: 40), Day 7 [N=224,209]
    217
    84
        Yamagata (≥1: 40), Day 0 [N=221,202]
    27
    12
        Yamagata (≥1: 40), Day 7 [N=224,209]
    216
    83
    No statistical analyses for this end point

    Secondary: Serum neutralising antibody titers against each of the vaccine strains after 1 dose of Fluarix Quadrivalent vaccine

    		 Close Top of page
    End point title
    		 Serum neutralising antibody titers against each of the vaccine strains after 1 dose of Fluarix Quadrivalent vaccine
    End point description
    Antibody titers were expressed as Geometric mean titers (GMTs). The vaccine strains included A/Christchurch/16/2010 ( H1N1), A/Victoria/361/2011 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens.
    End point type
    Secondary
    End point timeframe
    At Day 0 and Day 7
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    107
    109
    Units: Titer
    geometric mean (confidence interval 95%)
        H1N1, Day 0 [N=97,90]
    138.2 (97.4 to 196.2)
    48.3 (33.9 to 68.7)
        H1N1, Day 7 [N=107, 96]
    1500.9 (1172.7 to 1920.9)
    139.4 (78.8 to 246.8)
        H3N2, Day 0 [N=99,96]
    66.5 (55.9 to 79.2)
    82.8 (60.6 to 113.1)
        H3N2, Day 7 [N=104,100]
    422.9 (342.3 to 522.4)
    325.1 (187.1 to 564.7)
        Victoria, Day 0 [N=107,109]
    38.6 (29.7 to 50.3)
    22.2 (18.6 to 26.5)
        Victoria, Day 7 [N=107, 108]
    193.7 (154.7 to 242.6)
    47 (30.3 to 72.9)
        Yamagata, Day 0 [N=107,107]
    36.9 (34.2 to 39.8)
    30.8 (29 to 32.6)
        Yamagata, Day 7 [N=107,107]
    182.7 (157.7 to 211.8)
    51.7 (42.2 to 63.4)
    No statistical analyses for this end point

    Secondary: Serum anti-neuraminidase antibody titers against each of the vaccine strains after 1 dose of Fluarix Quadrivalent vaccine

    		 Close Top of page
    End point title
    		 Serum anti-neuraminidase antibody titers against each of the vaccine strains after 1 dose of Fluarix Quadrivalent vaccine
    End point description
    Antibody titers were expressed as GMTs. The vaccine strains included A/Christchurch/16/2010 ( H1N1), A/Victoria/361/2011 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens.
    End point type
    Secondary
    End point timeframe
    At Day 0 and Day 7
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    107
    109
    Units: Titer
    geometric mean (confidence interval 95%)
        H1N1, Day 0 [N=106,106]
    34.6 (25.3 to 47.3)
    24.1 (18.6 to 31.1)
        H1N1, Day 7 [N=106, 109]
    293.9 (247.2 to 349.3)
    41.3 (28.9 to 59)
        H3N2, Day 0 [N=107,106]
    38.4 (33.7 to 43.7)
    58.8 (47.2 to 73.4)
        H3N2, Day 7 [N=107, 109]
    189.4 (155.9 to 230.2)
    114.2 (84.1 to 155.2)
        Victoria, Day 0 [N=106,106]
    17.4 (14.2 to 21.3)
    14.3 (12.4 to 16.5)
        Victoria, Day 7 [N=106,109]
    90.6 (74.1 to 110.8)
    27.6 (19.4 to 39.1)
        Yamagata, Day 0 [N=106, 106]
    25.3 (21.6 to 29.6)
    15.4 (13.2 to 18)
        Yamagata, Day 7 [N=106,109]
    222 (185.7 to 265.4)
    40.6 (29.5 to 55.7)
    No statistical analyses for this end point

    Secondary: Vaccine response rate (VRR) for neutralising antibody titers against each of the four vaccine strains.

    		 Close Top of page
    End point title
    		 Vaccine response rate (VRR) for neutralising antibody titers against each of the four vaccine strains.
    End point description
    VRR was defined as the number of vaccinees who had either a pre-vaccination titer <cut-off and a post-vaccination titer ≥ 4-fold of half of the cut-off or a pre-vaccination titer ≥cut-off and at least a 4-fold increase in post-vaccination titers. The vaccine strains included A/Christchurch/16/2010 (H1N1), A/Victoria/361/2011 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens.
    End point type
    Secondary
    End point timeframe
    At Day 7 post dose 1
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    107
    108
    Units: Subjects
        H1N1 [N=97,89]
    74
    36
        H3N2 [N=97,94]
    72
    48
        Victoria [N=107,108]
    78
    24
        Yamagata [N=107,105]
    45
    15
    No statistical analyses for this end point

    Secondary: MGI for neutralising antibodies titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine.

    		 Close Top of page
    End point title
    		 MGI for neutralising antibodies titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine.
    End point description
    MGI was defined as the fold increase in serum HI GMT post-vaccination compared to Day 0. The vaccine strains included A/Christchurch/16/2010 (H1N1), A/Victoria/361/2011 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens.
    End point type
    Secondary
    End point timeframe
    At Day 7 post dose 1
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    107
    108
    Units: Fold increase
    geometric mean (confidence interval 95%)
        H1N1 [N=97, 89]
    10.6 (8.2 to 13.7)
    3.1 (2.3 to 4.2)
        H3N2 [N=97, 94]
    6.4 (5.4 to 7.6)
    4.5 (3.2 to 6.2)
        Victoria [N=107,108]
    5 (4.3 to 5.8)
    2.1 (1.6 to 2.8)
        Yamagata [N=107,105]
    5 (4.3 to 5.7)
    1.7 (1.4 to 2)
    No statistical analyses for this end point

    Secondary: Vaccine response rate(VRR) for anti-neuraminidase antibody titers against each of the four vaccine strains.

    		 Close Top of page
    End point title
    		 Vaccine response rate(VRR) for anti-neuraminidase antibody titers against each of the four vaccine strains.
    End point description
    VRR was defined as the number of vaccinees who had either a pre-vaccination titer <cut-off and a post-vaccination titer ≥ 4-fold of half of the cut-off or a pre-vaccination titer ≥cut-off and at least a 4-fold increase in post-vaccination titers. The vaccine strains included A/Christchurch/16/2010 (H1N1), A/Victoria/361/2011 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens.
    End point type
    Secondary
    End point timeframe
    At Day 7 post dose 1
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    107
    106
    Units: Subjects
        H1N1 [N=105,106]
    75
    31
        H3N2 [N=107,106]
    75
    31
        Victoria [N=105,106]
    79
    24
        Yamagata [N=105,106]
    90
    29
    No statistical analyses for this end point

    Secondary: MGI for anti-neuraminidase antibodies titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine.

    		 Close Top of page
    End point title
    		 MGI for anti-neuraminidase antibodies titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine.
    End point description
    MGI was defined as the fold increase in serum HI GMT post-vaccination compared to Day 0. The vaccine strains included A/Christchurch/16/2010 (H1N1), A/Victoria/361/2011 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens.
    End point type
    Secondary
    End point timeframe
    At Day 7 post dose 1
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    107
    106
    Units: Fold increase
    geometric mean (confidence interval 95%)
        H1N1 [N=105,106]
    8.3 (6.5 to 10.7)
    1.8 (1.5 to 2.1)
        H3N2 [N=105,106]
    5.2 (4.4 to 6)
    1.9 (1.5 to 2.4)
        Victoria [N=105,106]
    8.8 (7.5 to 10.2)
    2.7 (2.1 to 3.4)
        Yamagata [N=107,106]
    4.9 (4.2 to 5.8)
    2 (1.7 to 2.3)
    No statistical analyses for this end point

    Secondary: Number of subjects with HI antibody titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent Vaccine.

    		 Close Top of page
    End point title
    		 Number of subjects with HI antibody titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent Vaccine.
    End point description
    The cut-off values assessed were less than (<) 1:10, 1:10 to < 1:40,≥ 1:40, ≥1:60 and ≥1:80 . The vaccine strains included A/Christchurch/16/2010 ( H1N1), A/Victoria/361/2011 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens.
    End point type
    Secondary
    End point timeframe
    At Day 0 and Day 7
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    213
    179
    Units: Subjects
        H1N1, Day 0, <1:10 [N=210,173]
    32
    119
        H1N1, Day 7, <1:10 [N=213,179]
    4
    66
        H1N1, Day 0, 1:10 to <1:40 [N=210,173]
    178
    54
        H1N1, Day 7, 1:10 to <1:40 [N=213,179]
    209
    113
        H1N1, Day 0, ≥1:40 [N=210,173]
    87
    51
        H1N1, Day 7, ≥1:40 [N=213,179]
    206
    59
        H1N1, Day 0, ≥1:60 [N=210,173]
    73
    47
        H1N1, Day 7, ≥1:60 [N=213,179]
    204
    57
        H1N1, Day 0, ≥1:80 [N=210,173]
    73
    47
        H1N1, Day 7, ≥1:80 [N=213,179]
    204
    57
        H3N2, Day 0, <1:10 [N=210,173]
    90
    121
        H3N2, Day 7, <1:10 [N=213,179]
    6
    107
        H3N2, Day 0,1:10 to 1:40 [N=210,173]
    120
    52
        H3N2, Day 7,1:10 to 1:40 [N=213,179]
    207
    72
        H3N2, Day 0, ≥1:40 [N=210,173]
    29
    48
        H3N2, Day 7, ≥1:40 [N=213,179]
    182
    54
        H3N2, Day 0, ≥1:60 [N=210,173]
    12
    36
        H3N2, Day 7, ≥1:60 [N=213,179]
    147
    52
        H3N2, Day 0, ≥1:80 [N=210,173]
    12
    36
        H3N2, Day 7, ≥1:80 [N=213,179]
    147
    52
        Victoria, Day 0, <1:10 [N=210,173]
    33
    123
        Victoria, Day 7, <1:10 [N=213,179]
    0
    34
        Victoria, Day 0,1:10 to 1:40 [N=210,173]
    177
    50
        Victoria, Day 7,1:10 to 1:40 [N=213,179]
    213
    145
        Victoria, Day 0, ≥1:40 [N=210,173]
    68
    35
        Victoria, Day 7, ≥1:40 [N=213,179]
    206
    70
        Victoria, Day 0, ≥1:60 [N=210,173]
    40
    27
        Victoria, Day 7, ≥1:60 [N=213,179]
    182
    51
        Victoria, Day 0, ≥1:80 [N=210,173]
    40
    27
        Victoria, Day 7, ≥1:80 [N=213,179]
    182
    51
        Yamagata, Day 0, <1:10 [N=210,173]
    83
    142
        Yamagata, Day 7, <1:10 [N=213,179]
    2
    59
        Yamagata, Day 0,1:10 to 1:40 [N=210,173]
    127
    31
        Yamagata, Day 7,1:10 to 1:40 [N=213,179]
    211
    120
        Yamagata, Day 0, ≥1:40 [N=210,173]
    27
    10
        Yamagata, Day 7, ≥1:40 [N=213,179]
    205
    70
        Yamagata, Day 0, ≥1:60 [N=210,173]
    7
    4
        Yamagata, Day 7, ≥1:60 [N=213,179]
    177
    44
        Yamagata, Day 0, ≥1:80 [N=210,173]
    7
    4
        Yamagata, Day 7, ≥1:80 [N=213,179]
    177
    44
    No statistical analyses for this end point

    Secondary: Serum micro neutralizing(MN) antibody titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine.

    		 Close Top of page
    End point title
    		 Serum micro neutralizing(MN) antibody titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine.
    End point description
    MN antibody titers were expressed as geometric mean titers(GMTs). The vaccine strains included A/Christchurch/16/2010 (H1N1), A/Victoria/361/2011 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens.
    End point type
    Secondary
    End point timeframe
    At Day 0 and Day 7
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    100
    89
    Units: Titer
    geometric mean (confidence interval 95%)
        H1N1,Day 0[N=90,72]
    141.4 (97.6 to 205)
    47.3 (32.1 to 69.6)
        H1N1,Day 7[N=100,76]
    1461.3 (1132.8 to 1885.1)
    138.4 (71.9 to 266.4)
        H3N2,Day 0[N=92,76]
    60 (51.2 to 70.4)
    59.6 (42.5 to 83.7)
        H3N2,Day 7[N=97,80]
    374.6 (305.4 to 459.4)
    177.7 (97.4 to 324.2)
        Victoria,Day 0[N=100,89]
    37.1 (28.6 to 48.2)
    23.5 (19.1 to 28.9)
        Victoria,Day 7[N=100,88]
    189.9 (151.2 to 238.5)
    52 (31.3 to 86.3)
        Yamagata,day 0[N=100,87]
    37.1 (34.2 to 40.2)
    30.9 (28.9 to 32.9)
        Yamagata, Day 7[N=100,88]
    177.5 (154.2 to 204.5)
    49.8 (40.5 to 61.1)
    No statistical analyses for this end point

    Secondary: Serum anti-neuraminidase antibody titers against each of the vaccine strains after 1 dose of Fluarix Quadrivalent vaccine

    		 Close Top of page
    End point title
    		 Serum anti-neuraminidase antibody titers against each of the vaccine strains after 1 dose of Fluarix Quadrivalent vaccine
    End point description
    NI (Neuraminidase inhibitor) antibody titers were expressed as geometric mean titers(GMTs).The vaccine strains included A/Christchurch/16/2010 (H1N1), A/Victoria/361/2011 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens.
    End point type
    Secondary
    End point timeframe
    At Day 0 and Day 7
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    100
    89
    Units: Titer
    geometric mean (confidence interval 95%)
        H1N1, Day 0[N=99,86]
    34.8 (25.1 to 48.1)
    23.5 (17.8 to 31.1)
        H1N1, Day 7[N=99,89]
    287.1 (239.8 to 343.6)
    38.3 (25.7 to 57.1)
        H3N2, Day 0[N=100,86]
    35 (31.3 to 39.1)
    45.9 (36.7 to 57.4)
        H3N2, Day 7[N=100,89]
    175.8 (143.9 to 214.7)
    84.5 (60.7 to 117.6)
        Victoria, Day 0[N=99,86]
    16.8 (13.7 to 20.7)
    15 (12.7 to 17.6)
        Victoria, Day 7[N=99,89]
    89.2 (72.5 to 109.7)
    29.1 (19.6 to 43.2)
        Yamagata, Day 0[N=99,86]
    25.1 (21.3 to 29.5)
    15.4 (12.9 to 18.3)
        Yamagata, Day 7[N=100,89]
    216.5 (180.5 to 259.6)
    39.7 (27.9 to 56.6)
    No statistical analyses for this end point

    Secondary: Vaccine response rate(VRR) for serum neutralising antibody titers against each of the four vaccine strains

    		 Close Top of page
    End point title
    		 Vaccine response rate(VRR) for serum neutralising antibody titers against each of the four vaccine strains
    End point description
    VRR was defined as the number of vaccinees who had either a pre-vaccination titer <cut-off and a post-vaccination titer ≥ 4-fold of half of the cut-off or a pre-vaccination titer ≥cut-off and at least a 4-fold increase in post-vaccination titers. The vaccine strains included A/Christchurch/16/2010 (H1N1), A/Victoria/361/2011 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens.
    End point type
    Secondary
    End point timeframe
    At Day 7 post dose 1
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    100
    88
    Units: Subjects
        H1N1, Day 7[N=90,71]
    67
    28
        H3N2, Day 7[N=90,74]
    66
    31
        Victoria, Day 7[N=100,88]
    74
    21
        Yamagata, Day 7[N=100,86]
    42
    11
    No statistical analyses for this end point

    Secondary: MGI for neutralising antibodies titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine.

    		 Close Top of page
    End point title
    		 MGI for neutralising antibodies titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine.
    End point description
    MGI was defined as the fold increase in GMTs post-vaccination compared to Day 0. The vaccine strains included A/Christchurch/16/2010 (H1N1), A/Victoria/361/2011 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens.
    End point type
    Secondary
    End point timeframe
    At Day 7 post dose 1
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    100
    88
    Units: Fold Increase
    geometric mean (confidence interval 95%)
        H1N1, Day 7[N=90,71]
    10 (7.7 to 13.1)
    3.1 (2.2 to 4.3)
        H3N2, Day 7[N=90,74]
    6.2 (5.2 to 7.5)
    3.4 (2.4 to 4.9)
        Victoria, Day 7[N=100,88]
    5.1 (4.4 to 5.9)
    2.2 (1.6 to 3)
        Yamagata, Day 7[N=100,86]
    4.8 (4.2 to 5.4)
    1.6 (1.3 to 1.9)
    No statistical analyses for this end point

    Secondary: Vaccine response rate(VRR) for anti-neuraminidase antibodies against each of the four vaccine strains.

    		 Close Top of page
    End point title
    		 Vaccine response rate(VRR) for anti-neuraminidase antibodies against each of the four vaccine strains.
    End point description
    VRR was defined as the percentage of vaccinees who had either a pre-vaccination titer <cut-off and a post-vaccination titer ≥ 4-fold of half of the cut-off or a pre-vaccination titer ≥cut-off and at least a 4-fold increase in post-vaccination titers. The vaccine strains included A/Christchurch/16/2010 ( H1N1), A/Victoria/361/2011 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens.
    End point type
    Secondary
    End point timeframe
    At Day 7 post dose 1
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    100
    86
    Units: Subjects
        H1N1, Day 7[N=98,86]
    70
    23
        H3N2, Day 7[N=100,86]
    70
    22
        Victoria, Day 7[N=98,86]
    74
    20
        Yamagata, Day 7[N=99,86]
    85
    23
    No statistical analyses for this end point

    Secondary: MGI for anti-neuraminidase antibodies titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine

    		 Close Top of page
    End point title
    		 MGI for anti-neuraminidase antibodies titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine
    End point description
    MGI was defined as the fold increase in GMTs post-vaccination compared to Day 0. The vaccine strains included A/Christchurch/16/2010 (H1N1), A/Victoria/361/2011 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens.
    End point type
    Secondary
    End point timeframe
    At Day 7 post dose 1
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    100
    86
    Units: Fold increase
    geometric mean (confidence interval 95%)
        H1N1, Day 7[N=98,86]
    8.1 (6.2 to 10.5)
    1.7 (1.4 to 2.1)
        H3N2, Day 7[N=100,86]
    5 (4.2 to 6)
    1.8 (1.6 to 2.2)
        Victoria, Day 7[N=98,86]
    5.2 (4.5 to 6.1)
    1.9 (1.5 to 2.5)
        Yamagata, Day 7[N=99,86]
    8.7 (7.4 to 10.2)
    2.6 (2 to 3.5)
    No statistical analyses for this end point

    Secondary: Serum neutralising antibody titers against each of the vaccine strains after 1 dose of Fluarix Quadrivalent vaccine by age strata.

    		 Close Top of page
    End point title
    		 Serum neutralising antibody titers against each of the vaccine strains after 1 dose of Fluarix Quadrivalent vaccine by age strata.
    End point description
    Antibody titers were expressed as geometric mean titers. The vaccine strains included A/Christchurch/16/2010 (H1N1),A/Victoria/361/2011 (H3N2), A/Victoria/361/2011 and B/Hubei-Wujiagang/158/2009)(Yamagata) antigens. The humoral response in terms of neutralising antibodies for all vaccine strains were calculated by age stratum which included 17-29 months and 30-48 months age groups for both the Fluarix primed and unprimed groups.
    End point type
    Secondary
    End point timeframe
    At Day 0 and Day 7
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    54
    55
    Units: Titers
    geometric mean (confidence interval 95%)
        H1N1, Day 0,17-29M[N=47,44]
    76.8 (48.8 to 120.9)
    29 (18.7 to 44.9)
        H1N1, Day 7,17-29M [N=53,48]
    1112 (746 to 1657.8)
    53 (26.9 to 104.2)
        H1N1, Day 0,30-48M[N=50,46]
    240 (146.2 to 394.1)
    78.8 (46.6 to 133.1)
        H1N1, Day 7,30-48M[N=54,48]
    2014.5 (1517.5 to 2674.4)
    366.9 (155.6 to 865.4)
        H3N2,Day 0,17-29M[N=49,47]
    58.1 (46.3 to 72.9)
    74.5 (45.8 to 121.5)
        H3N2,Day 7,17-29M[N=51,50]
    370.5 (272.7 to 503.2)
    217.5 (97 to 488)
        H3N2,Day 0,30-48M[N=50,49]
    76 (58.2 to 99.1)
    91.5 (60.8 to 137.7)
        H3N2,Day 7,30-48M[N=53,50]
    480.3 (356.7 to 646.8)
    485.8 (226.2 to 1043.7)
        Victoria,Day 0,17-29M[N=53,54]
    29.2 (21.7 to 39.2)
    19.8 (15.9 to 24.8)
        Victoria,Day 7,17-29M[N=53,53]
    156.3 (119.7 to 204.2)
    35.5 (20 to 62.9)
        Victoria,Day 0,30-48M[N=54,55]
    50.9 (33.1 to 78.2)
    24.7 (18.8 to 32.6)
        Victoria,Day 7,30-48M[N=54,55]
    239.1 (166.7 to 343)
    61.8 (31.6 to 120.8)
        Yamagata, Day 0,17-29M[N=53,53]
    35.6 (32.3 to 39.2)
    29.6 (28 to 31.4)
        Yamagata, Day 7,17-29M[N=53,52]
    156.9 (129.4 to 190.3)
    45.6 (33.7 to 61.7)
        Yamagata, Day 0,30-48M[N=54,54]
    38.3 (34 to 43.1)
    32 (28.9 to 35.4)
        Yamagata, Day 7,30-48M[N=54,55]
    212.2 (170.1 to 264.7)
    58.3 (44.1 to 77)
    No statistical analyses for this end point

    Secondary: Serum anti-neuraminidase antibody titers against each of the vaccine strains after 1 dose of Fluarix Quadrivalent vaccine by age strata

    		 Close Top of page
    End point title
    		 Serum anti-neuraminidase antibody titers against each of the vaccine strains after 1 dose of Fluarix Quadrivalent vaccine by age strata
    End point description
    Antibody titers were expressed as geometric mean titers. The vaccine strains included A/Christchurch/16/2010(H1N1), A/Victoria/361/2011(H3N2),B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009(Yamagata) antigens. The humoral response in terms of anti-neuraminidase antibodies for all vaccine strains were calculated by age stratum which included 17-29 months and 30-48 months age groups for both the Fluarix primed and unprimed groups.
    End point type
    Secondary
    End point timeframe
    At Day 0 and Day 7
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    54
    55
    Units: Titers
    geometric mean (confidence interval 95%)
        H1N1, Day 0,17-29M[N=53,52]
    21.6 (15 to 31.3)
    15.8 (11.9 to 21.1)
        H1N1, Day 7,17-29M[N=53,54]
    246.3 (189.1 to 320.8)
    22.9 (14.9 to 35.1)
        H1N1, Day 0,30-48M[N=53,54]
    55.5 (34.2 to 89.9)
    36.1 (24.2 to 53.9)
        H1N1, Day 7,30-48M[N=53,55]
    350.7 (281.1 to 437.4)
    73.7 (42.9 to 126.7)
        H3N2, Day 0,17-29M[N=53,52]
    34.7 (29.2 to 41.2)
    49.8 (35.9 to 69.3)
        H3N2, Day 7,17-29M[N=53,54]
    158 (117.8 to 211.8)
    85.3 (55.4 to 131.4)
        H3N2, Day 0,30-48M[N=54,54]
    42.4 (34.9 to 51.6)
    69 (51.1 to 93.2)
        H3N2, Day 7,30-48M[N=54,55]
    226.4 (174.9 to 292.9)
    152.2 (98.5 to 235.1)
        Victoria, Day 0,17-29M[N=53,52]
    13.2 (11 to 16)
    13.1 (10.9 to 15.7)
        Victoria, Day 7,17-29M[N=53,54]
    68.8 (53.3 to 88.9)
    21.1 (13.4 to 33.2)
        Victoria, Day 0,30-48M[N=53,54]
    22.8 (16 to 32.4)
    15.7 (12.6 to 19.4)
        Victoria, Day 7,30-48M[N=53,55]
    119.2 (88.2 to 161.1)
    35.9 (21 to 61.4)
        Yamagata, Day 0,17-29M[N=53,52]
    20.5 (16.9 to 24.9)
    13.2 (11.1 to 15.8)
        Yamagata, Day 7,17-29M[N=53,54]
    181.4 (143.3 to 229.5)
    29.3 (19.5 to 44)
        Yamagata, Day 0,30-48M[N=53,54]
    31.1 (24.4 to 39.7)
    17.9 (13.8 to 23.1)
        Yamagata, Day 7,30-48M[N=53,55]
    271.8 (208.6 to 354.3)
    55.8 (34.4 to 90.5)
    No statistical analyses for this end point

    Secondary: Vaccine response rate(VRR) for serum neutralising antibody titers against each of the four vaccine strains by age strata

    		 Close Top of page
    End point title
    		 Vaccine response rate(VRR) for serum neutralising antibody titers against each of the four vaccine strains by age strata
    End point description
    VRR was defined as the percentage of vaccinees who had either a pre-vaccination titer <cut-off and a post-vaccination titer ≥ 4-fold of half of the cut-off or a pre-vaccination titer ≥cut-off and at least a 4-fold increase in post-vaccination titers. The vaccine strains included A/Christchurch/16/2010 (H1N1), A/Victoria/361/2011(H3N2), B/Brisbane/60/2008(Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens. The humoral response in terms of neutralising antibodies for all vaccine strains were calculated by age stratum which included 17-29 months and 30-48 months age groups for both the Fluarix primed and unprimed groups.
    End point type
    Secondary
    End point timeframe
    At Day 7 post dose 1
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    54
    55
    Units: Subjects
        H1N1, Day 7, 17-29M[47,44]
    39
    12
        H1N1, Day 7, 30-48M[50,45]
    35
    24
        H3N2, Day 7,17-29M[N=48,46]
    36
    19
        H3N2, Day 7,30-48M[N=49,48]
    36
    29
        Victoria, Day 7,17-29M[N=53,53]
    41
    9
        Victoria, Day 7,30-48M[N=54,55]
    37
    15
        Yamagata, Day 7,17-29M[N=53,51]
    17
    6
        Yamagata, Day 7,30-48M[N=54,54]
    28
    9
    No statistical analyses for this end point

    Secondary: MGI for neutralising antibodies titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine by age strata

    		 Close Top of page
    End point title
    		 MGI for neutralising antibodies titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine by age strata
    End point description
    MGI was defined as the fold increase in GMTs post-vaccination compared to Day 0.The vaccine strains included A/Christchurch/16/2010 (H1N1), A/Victoria/361/2011 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens.The humoral response in terms of neutralising antibodies for all vaccine strains were calculated by age stratum which included 17-29 months and 30-48 months age groups for both the Fluarix primed and unprimed groups.
    End point type
    Secondary
    End point timeframe
    At Day 7 post dose 1
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    54
    55
    Units: Fold Increase
    geometric mean (confidence interval 95%)
        H1N1, Day 7, 17-29M[N=47,44]
    13.1 (9.2 to 18.8)
    2 (1.4 to 3)
        H1N1, Day 7, 30-48M[N=50,45]
    8.7 (6 to 12.5)
    4.7 (3 to 7.3)
        H3N2, Day 7,17-29M[N=48,46]
    6.1 (4.8 to 7.7)
    3.4 (2.1 to 5.4)
        H3N2, Day 7,30-48M[N=49,48]
    6.7 (5.1 to 8.8)
    5.9 (3.8 to 9.2)
        Victoria, Day 7,17-29M[N=53,53]
    5.4 (4.4 to 6.5)
    1.8 (1.2 to 2.6)
        Victoria, Day 7,30-48M[N=54,55]
    4.7 (3.8 to 5.8)
    2.5 (1.6 to 3.8)
        Yamagata, Day 7,17-29M[N=53,51]
    4.4 (3.8 to 5.2)
    1.5 (1.2 to 2)
        Yamagata, Day 7,30-48M[N=54,54]
    5.5 (4.5 to 6.9)
    1.8 (1.4 to 2.4)
    No statistical analyses for this end point

    Secondary: Vaccine response rate(VRR) for anti-neuraminidase antibody titers against each of the four vaccine strains by age strata.

    		 Close Top of page
    End point title
    		 Vaccine response rate(VRR) for anti-neuraminidase antibody titers against each of the four vaccine strains by age strata.
    End point description
    VRR was defined as the percentage of vaccinees who had either a pre-vaccination titer <cut-off and a post-vaccination titer ≥ 4-fold of half of the cut-off or a pre-vaccination titer ≥cut-off and at least a 4-fold increase in post-vaccination titers. The vaccine strains included A/Christchurch/16/2010 (H1N1), A/Victoria /361/2011(H3N2), B/Brisbane /60/2008(Victoria ) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens. The humoral response in terms of anti-neuraminidase antibodies for all vaccine strains were calculated by age stratum which included 17-29 months and 30-48 months age groups for both the Fluarix primed and unprimed groups.
    End point type
    Secondary
    End point timeframe
    At Day 7 post dose 1
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    54
    54
    Units: Subjects
        H1N1, Day 7,17-29M[N=53,52]
    43
    11
        H1N1, Day 7,30-48M[N=52,54]
    32
    20
        H3N2, Day 7,17-29M[N=53,52]
    36
    8
        H3N2, Day 7,30-48M[N=54,54]
    39
    23
        Victoria, Day 7,17-29M[N=53,52]
    40
    8
        Victoria, Day 7,30-48M[N=52,54]
    39
    16
        Yamagata, Day 7, 17-29M[N=53,52]
    46
    10
        Yamagata, Day 7, 30-48M[N=52,54]
    44
    19
    No statistical analyses for this end point

    Secondary: MGI for anti-neuraminidase antibodies titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine by age strata.

    		 Close Top of page
    End point title
    		 MGI for anti-neuraminidase antibodies titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine by age strata.
    End point description
    MGI was defined as the fold increase in GMTs post-vaccination compared to Day 0. The vaccine strains included A/Christchurch/16/2010 (H1N1), A/Victoria/361/2011 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Hubei-Wujiagang/158/2009 (Yamagata) antigens. The humoral response in terms of anti-neuraminidase antibodies for all vaccine strains were calculated by age stratum which included 17-29 months and 30-48 months age groups for both the Fluarix primed and unprimed groups.
    End point type
    Secondary
    End point timeframe
    At Day 7 post dose 1
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    54
    54
    Units: Fold Increase
    geometric mean (confidence interval 95%)
        H1N1, Day 7,17-29M[53,52]
    11.4 (8.2 to 15.8)
    1.5 (1.2 to 1.9)
        H1N1, Day 7,30-48M[N=52,54]
    6 (4.1 to 8.8)
    2.1 (1.7 to 2.7)
        H3N2, Day 7,17-29M[N=53,52]
    4.6 (3.6 to 5.8)
    1.7 (1.4 to 2)
        H3N2, Day 7,30-48M[N=54,54]
    5.3 (4.2 to 6.8)
    2.3 (1.9 to 2.8)
        Victoria, Day 7,17-29M[N=53,52]
    5.2 (4.3 to 6.3)
    1.5 (1.1 to 2.1)
        Victoria, Day 7,30-48M[N=52,54]
    5.1 (4.1 to 6.5)
    2.3 (1.6 to 3.4)
        Yamagata, Day 7, 17-29M[N=53,52]
    8.8 (7.2 to 10.8)
    2.2 (1.5 to 3.2)
        Yamagata, Day 7, 30-48M[N=52,54]
    8.7 (6.9 to 11)
    3.2 (2.3 to 4.5)
    No statistical analyses for this end point

    Secondary: Number of subjects reporting any and grade 3 solicited local adverse events (AEs)

    		 Close Top of page
    End point title
    		 Number of subjects reporting any and grade 3 solicited local adverse events (AEs)
    End point description
    Solicited local AEs assessed were pain, redness and swelling. Any = any solicited local AE reported irrespective of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness and swelling was defined as redness/swelling above 50 millimeter (mm).
    End point type
    Secondary
    End point timeframe
    During a 7-day (Day 0 to 6) follow-up period after first vaccination
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    239
    228
    Units: Subjects
        Any Pain
    96
    61
        Grade 3 Pain
    2
    1
        Any Redness
    82
    48
        Grade 3 Redness
    2
    0
        Any Swelling
    49
    25
        Grade 3 Swelling
    2
    0
    No statistical analyses for this end point

    Secondary: Duration of solicted symptoms

    		 Close Top of page
    End point title
    		 Duration of solicted symptoms
    End point description
    Duration was defined as number of days with any grade of solicted local and/or general symptoms
    End point type
    Secondary
    End point timeframe
    During the 7-day (Days 0-6) post-vaccination Dose 1 period
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    96
    61
    Units: Days
    median (full range (min-max))
        Drowsiness
    1 (1 to 7)
    1 (1 to 4)
        Irritability/fussiness
    2 (1 to 7)
    2 (1 to 7)
        Loss of appetite
    2 (1 to 7)
    2 (1 to 5)
        Pain
    1 (1 to 5)
    1 (1 to 5)
        Redness
    2 (1 to 7)
    2 (1 to 6)
        Swelling
    2 (1 to 5)
    1 (1 to 5)
        Temperature
    1 (1 to 5)
    2 (1 to 6)
    No statistical analyses for this end point

    Secondary: Number of subjects reporting any, grade 3 and related solicited general symptoms.

    		 Close Top of page
    End point title
    		 Number of subjects reporting any, grade 3 and related solicited general symptoms.
    End point description
    Solicited general symptoms assessed were drowsiness, Irritability/Fussiness, loss of appetite and Temperature. Any Temperature = axillary temperature ≥37.5 degrees Celsius (°C). Any = any solicited general symptom reported irrespective of intensity and relationship to vaccination. Related = symptoms considered by the investigator to have a causal relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 Irritability/Fussiness = Crying that could not be comforted/prevented normal activity. Grade 3 loss of appetite = did not eat at all. Grade 3 temperature = axillary temperature > 39.0°C.
    End point type
    Secondary
    End point timeframe
    During the 7 days (Days 0 – 6) post dose 1 vaccination
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    238
    224
    Units: Subjects
        Any Drowsiness
    54
    44
        Grade 3 Drowsiness
    5
    1
        Related Drowsiness
    36
    28
        Any Irritability/Fussiness
    77
    59
        Grade 3 Irritability/Fussiness
    5
    5
        Related Irritability/Fussiness
    51
    43
        Any Loss of appetite
    51
    46
        Grade 3 Loss of appetite
    8
    5
        Related Loss of appetite
    31
    31
        Any Temperature
    13
    26
        Grade 3 Temperature
    2
    1
        Related Temperature
    6
    15
    No statistical analyses for this end point

    Secondary: Number of subjects reporting AEs with Medically Attended Visits (MAV)

    		 Close Top of page
    End point title
    		 Number of subjects reporting AEs with Medically Attended Visits (MAV)
    End point description
    MAVs were defined as an AEs with a medically-attended visits i.e. prompting emergency room (ER) visits, hospitalizations or physician visits and that were not routine visits for physical examination or vaccination. Any MAV was defined as at least one MAV experienced. Grade 3 was a MAV that prevented normal activities and related was defined as a MAV assessed by the investigator to be causally related to the study vaccination.
    End point type
    Secondary
    End point timeframe
    During the entire study period (Day 0 – Day 179)
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    241
    229
    Units: Subjects
        Any MAV
    149
    130
        Grade 3 MAV
    5
    8
        Related MAV
    0
    1
    No statistical analyses for this end point

    Secondary: Number of subjects reporting Potential Immune-Mediated Diseases (pIMDs)

    		 Close Top of page
    End point title
    		 Number of subjects reporting Potential Immune-Mediated Diseases (pIMDs)
    End point description
    pIMDs were defined as a subset of AEs that included autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have had an autoimmune aetiology. Any pIMDs= Any AEs that occured regardless of the relation with vaccination. Related pIMDs= Any pIMD assessed by the investigator as casually related to the study vaccination.
    End point type
    Secondary
    End point timeframe
    During the entire study period (Days 0 - 179)
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    241
    229
    Units: Subjects
        Any pIMD
    0
    0
        Related pIMD
    0
    0
    No statistical analyses for this end point

    Secondary: Number of subjects reporting any, grade 3 and related unsolicited AEs.

    		 Close Top of page
    End point title
    		 Number of subjects reporting any, grade 3 and related unsolicited AEs.
    End point description
    Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination. Grade 3 was an event that prevented normal activities and related was defined as an unsolicited AE assessed by the investigator to be causally related to the study vaccination.
    End point type
    Secondary
    End point timeframe
    Within 28 days (Days 0-27) after first vaccination
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    241
    229
    Units: Subjects
        Any Unsolicted AEs
    66
    66
        Grade 3 Unsolicted AEs
    6
    7
        Related Unsolicted AEs
    5
    3
    No statistical analyses for this end point

    Secondary: Number of subjects reporting any and related serious adverse events (SAEs)

    		 Close Top of page
    End point title
    		 Number of subjects reporting any and related serious adverse events (SAEs)
    End point description
    A serious adverse event was any untoward medical occurrence that: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.
    End point type
    Secondary
    End point timeframe
    During the entire study period (Day 0 – Day 179)
    End point values
    		 Fluarix Quadrivalent Primed Group Fluarix Quadrivalent Unprimed Group
    Number of subjects analysed
    241
    229
    Units: Subjects
        Any SAE(s)
    7
    8
        Related SAE(s)
    0
    0
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Serious Adverse Events: From Day 0 to Day 179; Solicited local and general symptoms: During the 7-day (Days 0-6) post-vaccination period; Unsolicited symptoms: During the 28-day (Day 0-27) post-vaccination period.
    Adverse event reporting additional description
    For the frequent adverse events, the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
    Assessment type
    		 Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    16.1
    Reporting groups
    Reporting group title
    Fluarix Quadrivalent Unprimed Group
    Reporting group description
    		 Subjects in this group were unprimed in the primary study 115345 (NCT01439360) and received 2 doses of Fluarix Quadrivalent vaccine at Days 0 and 28 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.

    Reporting group title
    Fluarix Quadrivalent Primed Group
    Reporting group description
    		 Subjects in this group were previously primed with 2 doses of Fluarix Quadrivalent vaccine in the primary study 115345 (NCT01439360) and received 1 dose of Fluarix Quadrivalent vaccine at Day 0 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.

    Serious adverse events
    		 Fluarix Quadrivalent Unprimed Group Fluarix Quadrivalent Primed Group
    Total subjects affected by serious adverse events
         subjects affected / exposed
    8 / 229 (3.49%)
    7 / 241 (2.90%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    Injury, poisoning and procedural complications
    Thermal burn
         subjects affected / exposed
    0 / 229 (0.00%)
    1 / 241 (0.41%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Inguinal hernia
         subjects affected / exposed
    1 / 229 (0.44%)
    0 / 241 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Adenoidal hypertrophy
         subjects affected / exposed
    1 / 229 (0.44%)
    0 / 241 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Upper respiratory tract inflammation
         subjects affected / exposed
    0 / 229 (0.00%)
    1 / 241 (0.41%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Urticaria
         subjects affected / exposed
    0 / 229 (0.00%)
    1 / 241 (0.41%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    0 / 229 (0.00%)
    1 / 241 (0.41%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Gastroenteritis
         subjects affected / exposed
    2 / 229 (0.87%)
    0 / 241 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bronchiolitis
         subjects affected / exposed
    1 / 229 (0.44%)
    0 / 241 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bronchitis
         subjects affected / exposed
    0 / 229 (0.00%)
    1 / 241 (0.41%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bronchopneumonia
         subjects affected / exposed
    0 / 229 (0.00%)
    1 / 241 (0.41%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Laryngitis
         subjects affected / exposed
    0 / 229 (0.00%)
    1 / 241 (0.41%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lymphadenitis bacterial
         subjects affected / exposed
    1 / 229 (0.44%)
    0 / 241 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Otitis media
         subjects affected / exposed
    0 / 229 (0.00%)
    1 / 241 (0.41%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Otitis media acute
         subjects affected / exposed
    0 / 229 (0.00%)
    1 / 241 (0.41%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pharyngitis
         subjects affected / exposed
    1 / 229 (0.44%)
    0 / 241 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonia bacterial
         subjects affected / exposed
    1 / 229 (0.44%)
    0 / 241 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rhinitis
         subjects affected / exposed
    0 / 229 (0.00%)
    1 / 241 (0.41%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Sinusitis
         subjects affected / exposed
    0 / 229 (0.00%)
    1 / 241 (0.41%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    		 Fluarix Quadrivalent Unprimed Group Fluarix Quadrivalent Primed Group
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    138 / 229 (60.26%)
    145 / 241 (60.17%)
    General disorders and administration site conditions
    Pain
    alternative assessment type: Systematic
         subjects affected / exposed [1]
    61 / 228 (26.75%)
    96 / 239 (40.17%)
         occurrences all number
    61
    96
    Redness
    alternative assessment type: Systematic
         subjects affected / exposed [2]
    48 / 228 (21.05%)
    82 / 239 (34.31%)
         occurrences all number
    48
    82
    Drowsiness
    alternative assessment type: Systematic
         subjects affected / exposed [3]
    44 / 224 (19.64%)
    54 / 238 (22.69%)
         occurrences all number
    44
    54
    Swelling
    alternative assessment type: Systematic
         subjects affected / exposed [4]
    25 / 228 (10.96%)
    49 / 239 (20.50%)
         occurrences all number
    25
    49
    Irritability/Fussiness
    alternative assessment type: Systematic
         subjects affected / exposed [5]
    59 / 224 (26.34%)
    77 / 238 (32.35%)
         occurrences all number
    59
    77
    Loss of Appetite
    alternative assessment type: Systematic
         subjects affected / exposed [6]
    46 / 224 (20.54%)
    51 / 238 (21.43%)
         occurrences all number
    46
    51
    Temperature
    alternative assessment type: Systematic
         subjects affected / exposed [7]
    26 / 224 (11.61%)
    13 / 238 (5.46%)
         occurrences all number
    26
    13
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    13 / 229 (5.68%)
    9 / 241 (3.73%)
         occurrences all number
    13
    9
    Notes
    [1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.
    [2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.
    [3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.
    [4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.
    [5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.
    [6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.
    [7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 19 05:43:53 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA